Curaxis elects Dr Bert Spilker to board
This article was originally published in Scrip
Curaxis Pharmaceuticals (US), an emerging speciality company with a hormone drug candidate for the treatment of Alzheimer's disease and multiple cancers, has elected Dr Bert Spilker to its board of directors. He is founder and president of Bert A Spilker & Associates, and was previously senior vice-president of scientific and regulatory affairs for PhRMA.
You may also be interested in...
Circassia is returning the US rights to two COPD drugs to AstraZeneca as it admits it cannot meet its debt payments from the deal.
At their second meeting on COVID-19, drug regulators from around the world have stressed the importance of large, multi-arm studies in generating the data needed for the approval of potential coronavirus therapies. The European Medicines Agency, which organized the meeting, has also announced a new coronavirus task force to identify promising drug candidates and help steer them through development to regulatory approval.